Arrowhead Pharmaceuticals rises on promising early-stage data for obesity treatments

Shares of drug developer Arrowhead Pharmaceuticals ARWR.O jump 15.3% to $73.66

Co says early-stage trial showed its experimental treatment ARO-INHBE, in combination with Eli Lilly's LLY.N tirzepatide, achieved an average 9.4% weight loss over 16 weeks in obese patients with type 2 diabetes

In another early-stage trial, co's other experimental gene-based therapy for obesity, ARO-ALK7, showed an average reduction of 88% in the ALK7 gene over 8 weeks

Targeting the ALK7 gene can help treat obesity and metabolic disorders by altering how fat cells store and burn energy

Both experimental treatments were well tolerated - ARWR

ARWR has more than tripled in the past 12 months